Lupus Nephritis
Belimumab becomes first FDA-approved drug for pediatric lupus nephritis
The FDA has approved GlaxoSmithKline’s belimumab for the treatment of children with active lupus nephritis who are also receiving standard therapy, according to a company press release.
‘Bad for patients’: Rheumatologists express dismay over Roe v. Wade reversal
In the wake of the Supreme Court’s decision overturning Roe v. Wade, rheumatologists and rheumatology associations are voicing concern over what the loss of federal abortion protections could mean for patients.
Q&A: Body image concerns in lupus leave patients feeling ‘betrayed,’ ‘out of control’
Although commonly referred to as an “invisible illness,” lupus — and some of its treatments — can manifest in ways that are not only visible, but also heavily impact the daily lives of patients.
‘Get rid of maintenance prednisone’: Steroid-sparing critical for non-renal lupus
Although patients with lupus nephritis may require prednisone maintenance, attempts should be made to reduce their steroid doses, said a speaker at The Future of Systemic Lupus Erythematosus Diagnosis and Treatment meeting.
First proposed definition for disease modification in lupus focuses on disease activity
The first proposed definition for disease modification in systemic lupus erythematosus, including lupus nephritis, requires “minimizing” disease activity with few treatment-associated toxicities, while slowing organ damage progression.
Q&A: CD6/ALCAM may hold key to more specific, effective therapies in lupus nephritis
Uncovering a viable biomarker in a historically challenging disease like lupus nephritis is tantamount to striking gold if it can be used for one important purpose: Predicting treatment response.
AKF launches campaign to involve underrepresented groups in kidney disease clinical trials
The American Kidney Fund announced a new campaign focused on encouraging “communities of color” to participate in kidney disease clinical trials.
AKF launches new campaign for prevention, management of lupus nephritis
Voclosporin for lupus nephritis reduces proteinuria with no eGFR change
Patients with lupus nephritis who receive voclosporin demonstrated “meaningful reductions” in proteinuria with no change in mean estimated glomerular filtration rate at 30 months, according to data presented at ACR Convergence 2021.
'It makes a difference where you live': Lupus nephritis mortality highest in central metros
Race and residence are both independently associated with lupus nephritis mortality, with Black patients and those living in large central metropolitan areas demonstrating the highest rates, according to data presented at ACR Convergence 2021.